W R Markesbery
Overview
Explore the profile of W R Markesbery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
257
Citations
11745
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nelson P, Kryscio R, Jicha G, Abner E, Schmitt F, Xu L, et al.
Neurology
. 2009 Oct;
73(14):1127-33.
PMID: 19805729
Background: Recent studies raised questions about the severity of cognitive impairment associated with dementia with Lewy bodies (DLB). However, there have been few analyses of large, multicenter data registries for...
12.
Iacono D, Markesbery W, Gross M, Pletnikova O, Rudow G, Zandi P, et al.
Neurology
. 2009 Jul;
73(9):665-73.
PMID: 19587326
Background: It is common to find substantial Alzheimer disease (AD) lesions, i.e., neuritic beta-amyloid plaques and neurofibrillary tangles, in the autopsied brains of elderly subjects with normal cognition assessed shortly...
13.
Jicha G, Schmitt F, Abner E, Nelson P, Cooper G, Smith C, et al.
Neurobiol Aging
. 2008 Nov;
31(10):1805-13.
PMID: 19026468
The mild cognitive impairment (MCI) stage of dementia with Lewy bodies (MCI-DLB) has not yet been defined, but is likely to differ in the MCI stage of Alzheimer's disease (MCI-AD)....
14.
Smith C, Chebrolu H, Markesbery W, Liu J
Neurol Res
. 2008 Sep;
30(10):1091-6.
PMID: 18768112
Objective: Delineation of gray matter (GM) structures on brain MRI scans is termed segmentation. Accuracy of segmentation is a key factor in the valid comparison of GM density and volume...
15.
Jicha G, Abner E, Schmitt F, Cooper G, Stiles N, Hamon R, et al.
Dement Geriatr Cogn Disord
. 2008 Aug;
26(2):187-92.
PMID: 18724049
Objective: Comparative analysis of subjects with mild cognitive impairment (MCI) diagnosed in a primary research setting and those seen in a tertiary care memory disorders clinic. Methods: Subjects who received...
16.
Lovell M, Lynn B, Xiong S, Quinn J, Kaye J, Markesbery W
Neurology
. 2008 May;
70(23):2212-8.
PMID: 18448869
Objective: To determine if an aberrant protein complex consisting of prostaglandin-d-synthase (PDS) and transthyretin (TTR) in CSF differentiates between subjects with Alzheimer disease (AD) and normal control (NC) subjects. Methods:...
17.
Smith C, Chebrolu H, Wekstein D, Schmitt F, Jicha G, Cooper G, et al.
Neurology
. 2007 Apr;
68(16):1268-73.
PMID: 17438217
Objective: To determine whether alterations of brain structure in normal aged individuals precede the development of mild cognitive impairment (MCI) or Alzheimer disease (AD). Background: Persons with MCI and AD...
18.
Smith J, Xiong S, Markesbery W, Lovell M
Neuroscience
. 2006 Apr;
140(3):879-88.
PMID: 16580781
Accumulating evidence suggests that a disruption of zinc (Zn) homeostasis may play a role in the pathogenesis of Alzheimer's disease. Although several Zn transporter proteins responsible for the regulation of...
19.
Kryscio R, Schmitt F, Salazar J, Mendiondo M, Markesbery W
Neurology
. 2006 Mar;
66(6):828-32.
PMID: 16567698
Objective: To identify risk factors associated with transitions from cognitively normal to various forms of mild cognitive impairment (MCI) and then from MCI into early dementia with death as a...
20.
Lovell M, Smith J, Xiong S, Markesbery W
Neurotox Res
. 2005 Sep;
7(4):265-71.
PMID: 16179263
Several studies show increased levels of zinc (Zn) in the Alzheimer's disease (AD) brain. More recently, alterations in synaptic Zn and Zn transporter proteins (ZnT) have been implicated in the...